Digital Companion Diagnostics Market Outlook 2026: Trends & Insights According to a newly published market research report by 24LifeSciences, global digital companion diagnostics market was valued at USD 5.2 billion in 2025 and is projected to reach USD 11.4 billion by 2034, growing at a compound annual growth rate (CAGR) of 10.5% during the forecast period. Digital companion diagnostics are specialized in vitro diagnostic tests that provide essential information for the safe and effective use of a corresponding therapeutic product. These advanced tools analyze specific biomarkers such as genetic mutations or protein expressions to identify patients who are most likely to benefit from a particular drug or who may be at increased risk of serious side effects. By enabling personalized treatment decisions, these diagnostics are fundamentally transforming patient care, particularly in complex therapeutic areas like oncology, where they guide targeted therapies and immunotherapies with unprecedented precision. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9120/digital-companion-diagnostics-market

AI & Molecular Diagnostics Reshaping Cervical Cancer Screening Market According to a newly published market research report by 24LifeSciences, global cervical cancer diagnostic testing market was valued at USD 6.19 billion in 2025 and is projected to grow from USD 6.47 billion in 2026 to reach USD 8.44 billion by 2034, growing at a compound annual growth rate (CAGR) of 4.6% during the forecast period. Cervical cancer diagnostic tests are essential medical procedures designed to detect precancerous and cancerous conditions in the cervix. These tests are critical for early intervention because cervical cancer is primarily caused by persistent infection with high-risk human papillomavirus (HPV) strains. The primary diagnostic modalities include Pap smear tests (Pap cytology), HPV DNA tests, colposcopy, and cervical biopsies, which are fundamental components of routine gynecological screening programs worldwide. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9355/cervical-cancer-diagnostic-testing-market

Top 10 Players Shaping the Global Hepatitis E Diagnostic Tests Market (2026–2034) According to a newly published market research report by 24LifeSciences, global Hepatitis E Diagnostic Tests market is valued at USD 40.1 million in 2026 and is projected to reach USD 47.1 million by 2034, growing at a compound annual growth rate (CAGR) of 2.4% during the forecast period. Hepatitis E diagnostic tests are critical medical tools designed to detect the presence of the Hepatitis E Virus (HEV), an RNA virus responsible for acute liver inflammation. These tests are indispensable for confirming infection, particularly during outbreaks and for high-risk populations such as pregnant women, immunocompromised individuals, and patients with pre-existing liver conditions. The primary diagnostic methodologies include Enzyme-Linked Immunosorbent Assay (ELISA) kits, which identify IgM and IgG antibodies, and advanced molecular techniques like Reverse Transcription-Polymerase Chain Reaction (RT-PCR) tests that detect viral RNA directly, offering high specificity and sensitivity. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9474/hepatitis-e-diagnostic-tests-market